HOME >> BIOLOGY >> NEWS
Study provides direct evidence of the role of telomeres in prostate cancer development

Boston, MA (October 16, 2002) Telomere shortening has been proposed as an early and prevalent marker of prostate cancer process, according to a study presented today at the American Association for Cancer Research's first annual Frontiers in Cancer Prevention Research meeting. Findings of the study provide the first direct evidence that human prostate cancer may progress, in the earliest phase, via chromosomal instability generated by short telomeres, by revealing that telomere shortening is a defining DNA alteration characterizing early prostate cancer lesions.

Telomere shortening may cause significant alterations at the chromosomal level of tumors initiating chromosomal instability and causing progression to a fully malignant state. Telomeres are specialized structures located at the end of chromosomal arms that stabilize and protect chromosomes. In addition, they play a role in preventing cells from reproducing uncontrollably.

"Our study found that short telomeres may represent useful markers for assessing effectiveness in cancer chemoprevention studies," according to Alan Meeker, research fellow and lead investigator of the study which was conducted by researchers at the Brady Urological Institute and Department of Pathology, The Johns Hopkins University School of Medicine. "In addition, if telomere shortening does play a direct, causal role in the cancer process, then it represents an important prevention target in its own right."

In order to test the hypothesis that telomere shortening is an early contributor to human prostate cancer, the researchers developed and validated a new test that allows direct assessment of telomere length in clinical specimens. This study probed telomere lengths in high-grade prostatic intraepithelial neoplasia (HGPIN), the pre-invasive precursor to prostate cancer. Results showed that the telomere lengths of epithelial cells (relating to cellular tissue) within HGPIN lesions were strikingly shorter t
'"/>

Contact: Aimee Frank
AMF@spectrumscience.com
202-369-1654
American Association for Cancer Research
16-Oct-2002


Page: 1 2 3

Related biology news :

1. Study: Emission of smog ingredients from trees is increasing rapidly
2. Study explores gene transfer to modify underlying course of Alzheimers disease
3. Study reveals why eyes in some paintings seem to follow viewers
4. Study by Israeli scientists provides insight on DNA code
5. Study reveals first genetic step necessary for prostate cancer growth
6. Study of flu patients reveals virus outsmarting key drug
7. Study in Science reveals recreational fishing takes big bite of ocean catch
8. Study suggests cell-cycle triggers might be cancer drug targets
9. Study narrows search for genes placing men at increased risk for prostate cancer
10. Study links high carbohydrate diet to increased breast cancer risk
11. Study explains spatial orientation differences between sexes

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/6/2017)... Feb. 6, 2017 According to Acuity ... driving border authorities to continue to embrace biometric ... are 2143 Automated Border Control (ABC) eGates and ... at more than 163 ports of entry across ... 2016 achieving a combined CAGR of 37%. APC ...
(Date:2/2/2017)... NEW YORK , Feb. 2, 2017  EyeLock ... has released a new white paper " What You ... The problem of ensuring user authenticity is a ... protect the authentication of users. However, traditional authentication schemes ... Biometric authentication offers an elegant ...
(Date:1/30/2017)...   Invitae Corporation (NYSE: NVTA ... today announced that it will report its fourth quarter ... on Monday, February 13, 2017, and Invitae,s management team ... p.m. Eastern / 1:45 p.m. Pacific. ... financial results, guidance, and recent developments and will spend ...
Breaking Biology News(10 mins):
(Date:2/16/2017)...  ArmaGen, Inc., a privately held biotechnology company ... neurological disorders, today reported preliminary evidence of cognitive ... investigational therapy for the treatment of Hurler and ... or MPS I). The initial results from an ... at the 13 th annual WORLD Symposium ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor ... a clinical-stage biotechnology company developing first-in-class biological therapies ... that it has elected to terminate its license ... peptide receptor agonists, including Cenderitide. "Our ... move as we prioritize our efforts to advance ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... SAN DIEGO , Feb. 16, 2017 /PRNewswire/ ... and innovative products to treat a variety of ... $5 million Series 1a financing and entered into ... Bank (SVB).  Dermata intends to use the capital ... of making major advancements in the treatment of ...
Breaking Biology Technology:
Cached News: